The ups and downs of paclitaxel-coated balloons and paclitaxel eluting stents: do the conclusions of SWEDEPAD 2 change our practice? Should we be concerned about mortality (again)?
The use of paclitaxel-coated devices (PCDs) in peripheral arterial disease continues to generate interest and controversy. The PCD journey to date has been a story of highs and lows. The recently published SWEDEPAD 1 and 2 trials have rekindled discussion regarding efficacy and a potential link to mortality.
Authors
- Patrick Haage
- Florian Wolf
- Robert A. Morgan
- Catharina S. P. van Rijswijk
- Stefan Müller-Hülsbeck
- Maria Antonella Ruffino
- Romaric Loffroy
- Lakshmi A. Ratnam
- Mohamad Hamady
- Fabrizio Fanelli
- Hicham Kobeiter
- Gerard O’Sullivan
Institutions
- St George's, University of London (GB)
- Université Paris-Est Créteil (FR)
- Leiden University Medical Center (NL)
- St George’s University Hospitals NHS Foundation Trust (GB)
- University Hospital Galway (IE)
- Laboratory for Biomedical Neurosciences (CH)
- Ospedale regionale di Lugano (CH)
- DIAKO (DE)
- Assistance Publique – Hôpitaux de Paris (FR)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Helios Universitätsklinikum Wuppertal (DE)
- St Mary's Hospital (GB)
- Maison des Sciences sociales et des Humanités de Dijon (FR)
- DIAKO (DE)
- University of Florence (IT)
- Imperial College London (GB)
- Medical University of Vienna (AT)
Publication Details
- Journal
- CVIR Endovascular
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1186/s42155-025-00645-9
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00